Evidence map›Paper›PMID 38129351›Full record

ArticleJournal of clinical immunology2023

Impact of Exposure to Vaccination and Infection on Cellular and Antibody Response to SARS-CoV-2 in CVID Patients Through COVID-19 Pandemic.

Giulia Anna Maria Luigia Costanzo, Carla Maria Deiana, Giuseppina Sanna, Andrea Perra, Marcello Campagna, Andrea Giovanni Ledda, Ferdinando Coghe, Vanessa Palmas, Riccardo Cappai, Aldo Manzin and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Giulia Anna Maria Luigia Costanzo *Department of Medical Sciences and Public Health, University of Cagliari, 09100, Cagliari, Italy.
Carla Maria Deiana *Department of Medical Sciences and Public Health, University of Cagliari, 09100, Cagliari, Italy.
Giuseppina SannaMicrobiology and Virology Unit, Department of Biomedical Sciences, University of Cagliari, 09042, Monserrato, Italy.
Andrea PerraOncology and Molecular Pathology Unit, Department of Biomedical Sciences, University of Cagliari, 09100, Cagliari, Italy.
Marcello CampagnaDepartment of Medical Sciences and Public Health, University of Cagliari, 09100, Cagliari, Italy.
Andrea Giovanni LeddaDepartment of Medical Sciences and Public Health, University of Cagliari, 09100, Cagliari, Italy.
Ferdinando CogheLaboratory Clinical Chemical Analysis and Microbiology, University Hospital of Cagliari, 09042, Monserrato, Italy.
Vanessa PalmasMicrobiology and Virology Unit, Department of Biomedical Sciences, University of Cagliari, 09042, Monserrato, Italy.
Riccardo CappaiLaboratory Clinical Chemical Analysis and Microbiology, University Hospital of Cagliari, 09042, Monserrato, Italy.
Aldo ManzinMicrobiology and Virology Unit, Department of Biomedical Sciences, University of Cagliari, 09042, Monserrato, Italy.
Luchino ChessaDepartment of Medical Sciences and Public Health, University of Cagliari, 09100, Cagliari, Italy.
Stefano Del GiaccoDepartment of Medical Sciences and Public Health, University of Cagliari, 09100, Cagliari, Italy.
Davide FirinuDepartment of Medical Sciences and Public Health, University of Cagliari, 09100, Cagliari, Italy. davide.firinu@unica.it.ORCID 0000-0002-5768-391X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study is to investigate the kinetics of response against SARS-CoV-2 elicited by vaccination and/or breakthrough infection (occurred after 3 doses of BNT162b2) in a cohort CVID patients.

methodsWe measured humoral and cellular immunity using quantitative anti-spike antibody (anti-S-IgG) and neutralization assay and specific interferon-gamma release assay (IGRA) before and after the third or fourth dose of BNT162b2 and/or after COVID-19.

resultsIn CVID, 58.3% seroconverted after 2 doses that increased to 77.8% after 3 doses. Between the second and third dose, there was a decline in humoral compartment that led to titers below the cutoff of 1:10 (MNA90%) in CVID. This was paralleled by a significantly lower proportion (30%) and reduced magnitude of the residual cellular response among CVID. The third dose achieved a lower titer of anti-S and nAb against the Wuhan strain than HC and significantly decreased the rate of those showing solely a positive neutralizing activity and those with simultaneous negativity of IGRA and nAbs; the differences in IGRA were overall reduced with respect to HC. At further sampling after breakthrough SARS-COV-2 infection, mostly in the omicron era, or fourth dose, 6 months after the last event, the residual nAb titer to Wuhan strain was still significantly higher in HC, while there was no significant difference of nAbs to BA.1. The rate of IGRA responders was 65.5% in CVID and 90.5% in HC (p=0.04), while the magnitude of response was similar. None of CVID had double negativity to nAbs and IGRA at the last sampling.

conclusionThis data shows an increase of adaptive immunity in CVID after mRNA vaccination in parallel to boosters, accrual number of exposures and formation of hybrid immunity.

Indexed as

COVID-19SARS-CoV-2AntibodiesAntibodies, NeutralizingAntibodies, ViralAntibody FormationBNT162 VaccineHumansPandemicsVaccinationAntibodiesAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineBNT162b2COVID-19Covi-FERONCVIDhybrid immunityinterferon-gamma release assayvaccination

Identifiers

PMID38129351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.